Hinge Health (NYSE:HNGE) Releases Earnings Results, Beats Estimates By $0.44 EPS

Hinge Health (NYSE:HNGE) announced its quarterly earnings results on Monday. The company reported $0.71 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.44, FiscalAI reports. Hinge Health had a net margin of 15.15% and a return on equity of 51.60%. The company had revenue of $234.97 million for the quarter.

Here are the key takeaways from Hinge Health’s conference call:

• Q3 results exceeded expectations, with revenue up 52% year over year to $235 million, an 88% gross margin, a 33% operating margin, and $120 million in free cash flow. The company raised its full-year 2026 revenue guidance to $879 million–$881 million and operating income guidance to $266 million–$268 million.
• Commercial momentum accelerated, with contracted clients up 28% year over year to 3,270, nearly 1 million SMB lives added through Q3, and more than 10 million lives across over 800 clients gaining access to multiple Hinge Health products. Management also cited rising win rates, strong health-plan partnerships, and increased member enrollment and renewals.
• Early results from the Migraine Care Program were encouraging, including a 23% reduction in monthly migraine days, a 28% reduction in attack duration, and clinically meaningful HIT-6 improvements for more than half of surveyed members. Migraine access has expanded to roughly 9 million lives, with most launches expected in early 2027.
• Hinge plans to launch its integrated GI Care Program in summer 2027, but management expects the offering’s revenue contribution to become meaningful mainly in 2028. The company is currently selling Cylinder’s existing GI solution and has expanded its GI client base by approximately 40% since announcing the acquisition.
• President Jim Pursley will step down at year-end to spend more time with his family and join Hinge Health’s board, with Chief Commercial Officer Aaryn Pure taking over go-to-market leadership. Management characterized the transition as orderly, but the change introduces leadership-transition risk.

Hinge Health Stock Up 0.7%

HNGE traded up $0.80 during trading on Monday, reaching $115.11. The company had a trading volume of 2,305,770 shares, compared to its average volume of 1,625,415. The business has a 50 day simple moving average of $98.13 and a 200-day simple moving average of $67.01. The stock has a market cap of $9.29 billion, a P/E ratio of 89.93 and a beta of 1.37. Hinge Health has a 52 week low of $30.08 and a 52 week high of $118.87.

Insider Activity

In other news, Chairman Gabriel Mecklenburg sold 250,000 shares of the firm’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $88.97, for a total value of $22,242,500.00. Following the completion of the sale, the chairman owned 250,000 shares in the company, valued at approximately $22,242,500. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Perez sold 150,000 shares of Hinge Health stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $89.44, for a total transaction of $13,416,000.00. Following the transaction, the chief executive officer directly owned 35,470 shares of the company’s stock, valued at approximately $3,172,436.80. This represents a 80.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 1,024,581 shares of company stock worth $95,632,761. 18.92% of the stock is currently owned by insiders.

Institutional Trading of Hinge Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Pathway Capital Management LP purchased a new stake in shares of Hinge Health in the third quarter worth approximately $7,730,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Hinge Health during the 3rd quarter valued at $2,520,000. ProShare Advisors LLC boosted its holdings in Hinge Health by 2.1% during the 3rd quarter. ProShare Advisors LLC now owns 5,588 shares of the company’s stock valued at $543,000 after acquiring an additional 117 shares during the period. Vise Technologies Inc. purchased a new position in Hinge Health during the 3rd quarter valued at $207,000. Finally, Schwartz Investment Counsel Inc. grew its position in Hinge Health by 0.8% in the 3rd quarter. Schwartz Investment Counsel Inc. now owns 61,310 shares of the company’s stock valued at $5,962,000 after acquiring an additional 510 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Stifel Nicolaus increased their price objective on shares of Hinge Health from $115.00 to $130.00 and gave the company a “buy” rating in a research report on Monday, October 26th. KeyCorp boosted their target price on shares of Hinge Health from $125.00 to $140.00 and gave the stock an “overweight” rating in a report on Friday, October 16th. Zacks Research cut shares of Hinge Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 11th. Weiss Ratings downgraded shares of Hinge Health from a “hold (c)” rating to a “hold (c-)” rating in a report on Thursday, October 8th. Finally, Citizens Jmp lifted their price target on Hinge Health from $96.00 to $107.00 and gave the stock a “market outperform” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $108.00.

About Hinge Health

Hinge Health is a digital healthcare company focused on musculoskeletal (MSK) conditions, including back and joint pain. The company provides virtual care programs designed to help members manage pain, improve mobility and reduce the need for more costly or invasive treatments.

Its platform combines personalized exercise therapy, behavioral support, education and access to clinical professionals. Hinge Health also uses technologies such as motion-sensing wearable devices and artificial intelligence to help guide exercises, monitor progress and tailor care plans to individual needs.

Hinge Health primarily serves employers and health plans, which offer its programs to eligible members in the United States.